The fear of boostering with a vaccine other than that used for the first dose is unfounded according to the Technical Scientific Committee. In Italy heterologous vaccination will be done, the vaccine mix. Anyone under 60 who has already taken the first dose of AstraZeneca will receive another mRna vaccine, then Pfizer or Moderna, for the second dose.
The Minister of Health Hope he explained that «heterologous vaccination has already been used by important countries such as Germany for several weeks, but also in other areas of the world, and the results are encouraging.
There are some studies that testify that the immune response is even better than that with two doses of the same vaccine ».
This practice does not have an official green light from Europe, but it has been used in medicine. Heterologous vaccination has already been done for influenza and hepatitis B also in Italy. The vaccine mix was done in France, Germany, Denmark, Sweden, Norway and the UK.
There are studies, reported by the Corriere della Sera, which confirm its validity. Like everything related to vaccination for Covid, it has limited data because never before had the path to create a vaccine been made so quickly. A Spanish study with volunteers who have had AstraZeneca e Pfizer says the mix would enhance the antibody response. There is German research that speaks of good tolerability with a slight increase in the immune response.
It is the Italian line. Anyone who has had the first dose of the AstraZeneca vaccine and will do the second with Pfizer or Moderna will get it greater coverage according to what they explained toActed sources close to the Cts. The recall will have to be done within the twelfth week. Each region will have to adapt.
The best result would come from the different technologies used for the vaccine which would lead to a diversified immune response. The immune system would be better prepared to fight the virus, with more weapons at its disposal, knowing it with the method a mRna messenger which carries genetic material of SARS-CoV-2 to build the Spike protein and with the a viral vector which carries a harmless virus. The Spike protein is the same, which makes virologists optimistic.
After the case of Camilla, who died in Genoa, there have been controversies for the Open Day. However, experts do not report a greater danger. Just a different statistical picture. A month ago the circulation of the virus was high: the risk of death from Covid was 8 cases in 100 thousand, that of lethal thrombosis was 1.1 in 100 thousand. Now the probability of developing a lethal form of Covid is 0.68 per 100,000, lower than the risk of thrombosis.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
